N-环己基-2-甲基丙酰胺 | 6282-96-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-环己基-2-甲基丙酰胺
• 英文名称: N-cyclohexylisobutyramide
• 英文别名: n-Cyclohexyl-2-methylpropanamide
• CAS: 6282-96-8
• 化学式: C₁₀H₁₉NO
• mdl: MFCD00964544
• 分子量: 169.267
• InChiKey: NPFIXJIFUHTLRP-UHFFFAOYSA-N

物化性质

• 熔点：
  119 °C
• 沸点：
  311.3±9.0 °C(Predicted)
• 密度：
  0.93±0.1 g/cm3(Predicted)
• 保留指数：
  1392

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-环己基-2-甲基丙酰胺 在 三乙基硼 、 苯硅烷 、 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 48.0h， 以98%的产率得到N-(2-methylpropylidene)cyclohexanamine
  参考文献：
  名称：

  用于硅烷还原酰胺的BEt 3基催化剂

  摘要：

  本文报道了一种简单但实用的催化体系的开发，该体系用于用氢硅烷或氢硅氧烷选择性还原酰胺。发现低成本且易于获得的三乙基硼烷（在THF中为1.0 M）与催化量的碱金属碱结合，可催化所有三种酰胺类别（叔，仲和伯酰胺）的还原反应，从而在室温下形成胺。温和的条件。另外，还可以通过使用BEt 3和碱的适当组合来实现将仲酰胺选择性转化为醛亚胺和将伯酰胺选择性转化为腈。这些赌注3的范围碱催化的酰胺氢化硅烷化反应已被深入研究。机理研究的初步结果表明，经过改进的Piers硅烷Si–H···B活化方式，其中BEt 3提取氢化物的过程是通过烷氧基或氢氧根阴离子与Si中心的配位来促进的。

  DOI：

  10.1021/acs.joc.9b00277
• 作为产物：
  描述：

  环己胺 在 高氯酸四乙基铵 、 三乙胺 作用下， 以 氯仿 、 乙腈 为溶剂， 反应 5.0h， 生成 N-环己基-2-甲基丙酰胺
  参考文献：
  名称：

  Maran, Flavio; Vianello, Elio; D'Angeli, Ferruccio, Journal of the Chemical Society. Perkin transactions II, 1987, p. 33 - 39

  摘要：

  DOI：
• 作为试剂：
  描述：

  triphenylmethyl p-cyanophenylsulfide 在 N-环己基-2-甲基丙酰胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以84%的产率得到三苯基甲烷
  参考文献：
  名称：

  Electron-transfer bond-breaking processes: an example of nonlinear activation-driving force relationship in the reductive cleavage of the carbon-sulfur bond

  摘要：

  The heterogeneous (electrode) and homogeneous electron transfer (ET) to triphenylmethyl p-cyanophenyl sulfide in N,N'-dimethylformamide is shown to involve the irreversible reductive cleavage of the C(alkyl)-S sigma-bond through a sequential charge-transfer/bond-breaking pathway. The intermediate formation of the sulfide anion radical, whose lifetime has been determined to be ca. 10 ns, evidences the outer-sphere nature of the initial ET. The kinetics of this step has been analyzed as a function of the reaction free energy. Heterogeneous rate constants have been determined as a function of the applied potential from voltammetric curves and their convolution. The kinetics of the homogeneous ET from a series of substituted azobenzene anion radicals has been investigated by voltammetric redox 'catalysis. Both the homogeneous and the heterogeneous reactions show a quadratic dependence of the activation free energy on the driving force. The rate constant data have been treated in terms of classical ET theories in order to obtain the corresponding thermodynamic and kinetic parameters. Noteworthy, the values of the standard potential for the sulfide/sulfide anion radical redox couple, derived in the treatment of the two independent sets of homogeneous and heterogeneous data, are practically coincident. Structural parameters, from semiempirical MO calculations on azobenzene and its anion radical have been used to evaluate the azobenzene contribution to the cross ET activation energy and consequently to estimate, by comparison with the experimental results, the electron-exchange activation energy for the sulfide. The transition from the neutral sulfide to its anion radical involves relevant variations of the internal coordinates, in agreement with the very fast anion radical fragmentation.

  DOI：

  10.1021/j100103a026

文献信息

• IDO INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160289171A1

  公开（公告）日：2016-10-06

  There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

  已披露的化合物可调节或抑制吲哌酮胺2,3-二氧化酶（IDO）的酶活性，含有该化合物的药物组合物以及利用本发明的化合物治疗增殖性疾病，如癌症、病毒感染和/或炎症性疾病的方法。
• Catalytic Hydrogenation of Amides to Amines under Mild Conditions
  作者：Mario Stein、Bernhard Breit

  DOI：10.1002/anie.201207803

  日期：2013.2.18

  Under (not so much) pressure: A general method for the hydrogenation of tertiary and secondary amides to amines with excellent selectivity using a bimetallic Pd–Re catalyst has been developed. The reaction proceeds under low pressure and comparatively low temperature. This method provides organic chemists with a simple and reliable tool for the synthesis of amines.

  在（不是很大）压力下：已开发出一种使用双金属Pd-Re催化剂将叔酰胺和仲酰胺氢化成胺的通用方法，具有优异的选择性。反应在低压和较低温度下进行。该方法为有机化学家提供了一种简单可靠的胺合成工具。
• [EN] INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)<br/>[FR] INHIBITEUR DE L'INDOLÉAMINE-2,3-DIOXYGÉNASE (IDO)
  申请人：INVENTISBIO INC

  公开号：WO2017139414A1

  公开（公告）日：2017-08-17

  The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases). Also, provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

  本公开提供了式（I）的化合物。本文描述的化合物可能在治疗与IDO相关的疾病方面有用，例如癌症或传染病（例如病毒或细菌感染性疾病）。本公开还提供了包括或使用本文描述的化合物的药物组合物、试剂盒、方法和用途。
• Controlled and Chemoselective Reduction of Secondary Amides
  作者：Guillaume Pelletier、William S. Bechara、André B. Charette

  DOI：10.1021/ja105194s

  日期：2010.9.22

  presence of 2-fluoropyridine. The electrophilic activated amide can then be reduced to the corresponding iminium using triethylsilane, a cheap, rather inert, and commercially available reagent. Imines can be isolated after a basic workup or readily transformed to the aldehydes following an acidic workup. The amine moiety can be accessed via a sequential reductive amination by the addition of silane and

  该通讯描述了一种不含金属的方法，该方法涉及在环境压力和温度下以良好至极好的收率将仲酰胺有效且受控地还原为亚胺、醛和胺。该方法包括在 2-氟吡啶存在下用三氟甲磺酸酐对仲酰胺进行化学选择性活化。然后可以使用三乙基硅烷（一种廉价、惰性且可商购的试剂）将亲电活化的酰胺还原为相应的亚胺鎓。亚胺可以在碱性处理后分离，也可以在酸性处理后容易地转化为醛。通过在一锅反应中加入硅烷和 Hantzsch 酯氢化物，可以通过顺序还原胺化获得胺部分。而且，
• PYRROLIDINYL SULFONE RORGAMMA MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191483A1

  公开（公告）日：2015-07-09

  Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中所有取代基都在此定义。还提供了包含相同成分的药物组合物。这类化合物和组合物在调节细胞中RORγ活性的方法和治疗受疾病或紊乱困扰的主体中是有用的，例如，主体将从调节RORγ活性中获益的自免疫和/或炎症紊乱。